

Ezra E Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120080/publications.pdf>

Version: 2024-02-01

128
papers

12,311
citations

38742
50
h-index

27406
106
g-index

133
all docs

133
docs citations

133
times ranked

14591
citing authors

#	ARTICLE	IF	CITATIONS
1	Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. Journal of Otolaryngology - Head and Neck Surgery, 2022, 51, 5.	1.9	3
2	Analysis of <i>CDK12</i> alterations in a pan-cancer database. Cancer Medicine, 2022, 11, 753-763.	2.8	6
3	Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers. Cancers, 2022, 14, 33.	3.7	17
4	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal of the National Cancer Institute, 2021, 113, 171-181.	6.3	25
5	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology, 2021, 34, 532-541.	5.5	63
6	The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification. Clinical Cancer Research, 2021, 27, 689-703.	7.0	113
7	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology, 2021, 156, 281-293.	0.6	157
8	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2021, 22, 450-462.	10.7	287
9	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nature Communications, 2021, 12, 2383.	12.8	39
10	Did Everolimus Break the Rules?. Clinical Cancer Research, 2021, 27, 3807-3808.	7.0	1
11	Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncology, The, 2021, 22, 883-892.	10.7	116
12	Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clinical Cancer Research, 2021, 27, 6075-6082.	7.0	40
13	Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities. Frontiers in Oncology, 2021, 11, 738626.	2.8	9
14	Inevitable Progress-Relying on the Immune System, Not Chance. Clinical Cancer Research, 2021, , clincanres.3739.2021.	7.0	0
15	Selection of Head and Neck Cancer Patients for Intensive Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 157-166.	0.8	10
16	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research, 2020, 26, 5153-5161.	7.0	58
17	Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. Journal of Clinical Oncology, 2020, 38, 2427-2437.	1.6	88
18	Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer, 2020, 126, 3972-3981.	4.1	34

#	ARTICLE	IF	CITATIONS
19	B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 3345-3359.	7.0	117
20	Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. <i>Translational Cancer Research</i> , 2020, 9, 203-209.	1.0	15
21	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 157-167.	4.1	21
22	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447.	2.1	16
23	Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. <i>Biomaterials</i> , 2020, 248, 120032.	11.4	14
24	HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. <i>Cancer Research</i> , 2020, 80, 732-746.	0.9	36
25	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
26	p16 status and choice of chemotherapy in the KEYNOTE-040 study – Authors' reply. <i>Lancet</i> , The, 2019, 394, 1323.	13.7	0
27	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223.	7.0	85
28	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019, 17, 429.	4.4	5
29	A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. , 2019, 7, 342.		40
30	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019, 10, 5546.	12.8	98
31	Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. <i>Cancer Immunology Research</i> , 2019, 7, 40-49.	3.4	17
32	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167.	13.7	1,153
33	Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. <i>Oral Oncology</i> , 2018, 80, 16-22.	1.5	42
34	Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. <i>Journal of Cancer Education</i> , 2018, 33, 622-626.	1.3	20
35	Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer. <i>JAMA Oncology</i> , 2018, 4, 989.	7.1	0
36	Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. <i>Frontiers in Oncology</i> , 2018, 8, 435.	2.8	18

#	ARTICLE	IF	CITATIONS
37	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 309-317.	2.3	12
38	Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1393-1399.	6.3	43
39	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 246-253.	2.1	73
40	Serum antibodies open the door to prediction and prognostication in human papillomavirus-related head and neck cancer. <i>Cancer</i> , 2017, 123, 4310-4313.	4.1	1
41	Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. <i>Annals of Oncology</i> , 2017, 28, 2526-2532.	1.2	70
42	Considering the survivorship care needs of head and neck cancer survivors. <i>Oral Oncology</i> , 2016, 57, 61-62.	1.5	0
43	American Cancer Society Head and Neck Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 203-239.	329.8	419
44	Multidisciplinary Care of Laryngeal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 717-724.	2.5	35
45	PI3K δ is a molecular switch that controls immune suppression. <i>Nature</i> , 2016, 539, 437-442.	27.8	884
46	Postoperative Management of High-Risk Resectable Head and Neck Cancer. , 2016, , 607-615.		0
47	Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. <i>Nature Communications</i> , 2016, 7, 13019.	12.8	51
48	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	1.6	141
49	Erlotinib and the Risk of Oral Cancer. <i>JAMA Oncology</i> , 2016, 2, 209.	7.1	111
50	A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. <i>PLoS ONE</i> , 2016, 11, e0152995.	2.5	17
51	The Rise of HPV-Positive Oropharyngeal Cancers in the United States. <i>Cancer Prevention Research</i> , 2015, 8, 9-11.	1.5	21
52	Reply to S. Chakraborty et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 968-968.	1.6	0
53	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2015, 51, 291-298.	1.5	136
54	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. <i>Cancer Letters</i> , 2015, 359, 269-274.	7.2	9

#	ARTICLE	IF	CITATIONS
55	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Targeted Oncology, 2015, 10, 501-508.	3.6	22
56	Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncology, 2015, 51, 399-408.	1.5	19
57	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research, 2015, 21, 5092-5099.	7.0	3
58	Lenvatinib in Advanced, Radioactive Iodine-131 Refractory, Differentiated Thyroid Carcinoma. Clinical Cancer Research, 2015, 21, 5420-5426.	7.0	22
59	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2015, 33, 3305-3313.	1.6	269
60	Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 53-58.	1.5	26
61	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2015, 21, 632-641.	7.0	525
62	p62/SQSTM1 Accumulation in Squamous Cell Carcinoma of Head and Neck Predicts Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitors. PLoS ONE, 2014, 9, e90171.	2.5	26
63	A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemotherapy and Pharmacology, 2014, 74, 1261-1270.	2.3	44
64	Efficient Cisplatin Prodrug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles with a Living System. Advanced Materials Interfaces, 2014, 1, 1400182.	3.7	22
65	Magnetomicelles: Efficient Cisplatin Prodrug Delivery Visualized with Sub-100 nm Resolution: Interfacing Engineered Thermosensitive Magnetomicelles With a Living System (Adv. Mater. Interfaces) Tj ETQq1 10.784314orgBT /Over	3.7	22
66	Race and competing mortality in advanced head and neck cancer. Oral Oncology, 2014, 50, 40-44.	1.5	27
67	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemotherapy and Pharmacology, 2014, 73, 1227-1239.	2.3	73
68	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2014, 32, 2735-2743.	1.6	458
69	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nature Genetics, 2014, 46, 939-943.	21.4	126
70	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer, 2014, 120, 2694-2703.	4.1	106
71	The ACR appropriateness criteria® for thyroid carcinoma: Searching for consensus in a rapidly evolving area. Oral Oncology, 2014, 50, 575-576.	1.5	0
72	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. PLoS ONE, 2014, 9, e102112.	2.5	14

#	ARTICLE	IF	CITATIONS
73	Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. <i>Journal of Geriatric Oncology</i> , 2013, 4, 327-333.	1.0	33
74	Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. <i>Molecular Oncology</i> , 2013, 7, 359-368.	4.6	37
75	Open Access in biomedical sciences: What the current turning point means more specifically to Oral Oncology contributors and readers. <i>Oral Oncology</i> , 2013, 49, 985-986.	1.5	3
76	Multidisciplinary Care of the Patient with Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 179-215.	1.5	23
77	Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. <i>Oral Oncology</i> , 2013, 49, 1025-1031.	1.5	16
78	Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. <i>Clinical Cancer Research</i> , 2012, 18, 4785-4793.	7.0	61
79	A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 2336-2343.	7.0	104
80	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. <i>Clinical Cancer Research</i> , 2012, 18, 2056-2065.	7.0	141
81	Novel targeted therapies in head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 281-295.	4.1	11
82	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2012, 48, 887-892.	1.5	42
83	Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. <i>Oral Oncology</i> , 2012, 48, 1025-1030.	1.5	13
84	Chemoradiation for patients with large-volume laryngeal cancers. <i>Head and Neck</i> , 2012, 34, 1162-1167.	2.0	26
85	Stereotactic body radiotherapy for multisite extracranial oligometastases. <i>Cancer</i> , 2012, 118, 2962-2970.	4.1	295
86	Current Treatment Options for Metastatic Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 35-46.	3.0	197
87	Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non-Small-Cell Lung Cancer, A Phase II Trial. <i>Clinical Lung Cancer</i> , 2012, 13, 123-128.	2.6	10
88	Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer. <i>PLoS Computational Biology</i> , 2012, 8, e1002350.	3.2	75
89	Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. <i>Translational Research</i> , 2011, 157, 265-272.	5.0	42
90	Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, e17-e19.	1.2	8

#	ARTICLE	IF	CITATIONS
91	Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. <i>Cancer</i> , 2011, 117, 4671-4678.	4.1	68
92	The Next Phase of Chemoprevention Research. <i>Cancer Prevention Research</i> , 2011, 4, 293-295.	1.5	0
93	Factors Associated With Long-term Speech and Swallowing Outcomes After Chemoradiotherapy for Locoregionally Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2010, 136, 1226.	1.2	17
94	Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3336-3343.	1.6	75
95	A Genome-Wide Screen for Microdeletions Reveals Disruption of Polarity Complex Genes in Diverse Human Cancers. <i>Cancer Research</i> , 2010, 70, 2158-2164.	0.9	72
96	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 358-365.	2.5	61
97	New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Cancer Research</i> , 2010, 16, 2489-2495.	7.0	102
98	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2009, 69, 3021-3031.	0.9	236
99	A Feed-Forward Loop Involving Protein Kinase C α and MicroRNAs Regulates Tumor Cell Cycle. <i>Cancer Research</i> , 2009, 69, 65-74.	0.9	99
100	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1864-1871.	1.6	353
101	Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. <i>Head and Neck</i> , 2009, 31, 1013-1021.	2.0	53
102	Personalizing cancer care: updates on head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1219-1222.	2.4	0
103	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. <i>Lancet Oncology</i> , The, 2009, 10, 247-257.	10.7	263
104	Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. <i>Ecological Management and Restoration</i> , 2008, 21, 514-521.	0.4	17
105	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4708-4713.	1.6	593
106	Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2008, 134, 1060.	1.2	53
107	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	1.6	240
108	Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors. <i>Current Cancer Drug Targets</i> , 2007, 7, 666-673.	1.6	19

#	ARTICLE	IF	CITATIONS
109	A Disturbance in the Force of Mitochondrial Mutations in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2007, 13, 4317-4319.	7.0	0
110	A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. <i>Cancer Investigation</i> , 2007, 25, 435-444.	1.3	10
111	Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 678-684.	0.8	38
112	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. <i>Quality of Life Research</i> , 2007, 16, 1615-1626.	3.1	24
113	Planned Post-Chemoradiation Neck Dissection: Significance of Radiation Dose. <i>Laryngoscope</i> , 2006, 116, 33-36.	2.0	61
114	Epidermal growth factor receptor directed therapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 25-43.	4.4	46
115	A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 766-770.	3.4	106
116	Role of Epidermal Growth Factor Receptor Pathway Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 2659-2665.	1.6	144
117	High Survival and Organ Function Rates After Primary Chemoradiotherapy for Intermediate-Stage Squamous Cell Carcinoma of the Head and Neck Treated in a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 3438-3444.	1.6	18
118	Protein Kinase C η Mediates Epidermal Growth Factor Induced Growth of Head and Neck Tumor Cells by Regulating Mitogen-Activated Protein Kinase. <i>Cancer Research</i> , 2006, 66, 6296-6303.	0.9	70
119	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. <i>Clinical Cancer Research</i> , 2005, 11, 8105-8108.	7.0	125
120	Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2005, 11, 8418-8424.	7.0	224
121	Targeted Therapies in Head and Neck Cancer. , 2005, , 239-261.		0
122	Novel therapeutic targets in squamous cell carcinoma of the head and neck. <i>Seminars in Oncology</i> , 2004, 31, 755-768.	2.2	19
123	The Expanding Role of Systemic Therapy in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1743-1752.	1.6	199
124	Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 81-90.	2.2	6
125	Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2003, 21, 1980-1987.	1.6	568
126	An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4546-4552.	1.6	135

#	ARTICLE	IF	CITATIONS
127	Treatment of metastatic urothelial cancer in the post-MVAC era. World Journal of Urology, 2001, 19, 126-132.	2.2	3
128	Locally advanced non-small cell lung cancer. Current Treatment Options in Oncology, 2001, 2, 27-42.	3.0	0